Top

International Journal of Clinical Oncology

Published in:

01-06-2017 | Original Article

Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma

Authors: Toshihiko Hayashi, Hiroshi Furukawa, Takashi Kitamura, Ryuji Shichinohe, Naoki Murao, Akihiko Oyama, Emi Funayama, Taku Maeda, Yuhei Yamamoto

Published in: International Journal of Clinical Oncology | Issue 3/2017

Abstract

Background

Past studies showed that integumentectomy and incontinuity could be effective procedures in the surgical management of melanoma patients. The present study reports on the historical background of these procedures. In addition, we analyze the ICG assisted integumentectomy and incontinuity techniques and algorithms that we had created when performing this procedure.

Method

In accordance with our algorithm, we performed ICG assisted integumentectomy/incontinuity procedures on 17 patients with stage III melanomas between 2008 and 2016. We also investigated the locoregional recurrence rate in a control group comprising 60 patients at stage III without using the algorithm.

Results

The former group exhibited a tendency of locoregional recurrence rate suppression. Melanoma cells in the dissected intervening tissue were microscopically identified in 2 out of 17 cases.

Conclusions

Our ICG assisted integumentectomy or incontinuity procedures could be effective in controlling locoregional recurrence rates in melanoma cases. Moreover, our method can be generally applied because the dissection is only performed within the lymphatic pathway region identified using indocyanine green.

Hueston JT (1970) lntegumentectomy for malignant melanoma of the limbs. Aust N Z J Surg 40:114–118CrossRefPubMed

Jones RF, Dickinson WE (1972) Total integumentectomy of the leg for multiple in-transit metastases of melanoma. Am J Surg 123:588–590CrossRefPubMed

Shah JP, Goldsmith HS (1970) Incontinuity versus discontinuous lymph node dissection for malignant melanoma. Cancer 26:610–614CrossRefPubMed

Fortner JG, Schottenfeld D, Maclean BJ (1975) En bloc resection of primary melanoma with regional lymph node dissection. Arch Surg 110:674–676CrossRefPubMed

Fujiwara M, Suzuki A, Mizukami T et al (2010) Mid-arm lymph nodes dissection for melanoma. J Plast Reconstr Aesthet Surg 63:1561–1564CrossRefPubMed

Hayashi T, Furukawa H, Tsutsumida A et al (2010) A false-negative sentinel lymph node in the parotid gland of a melanoma patient: a new algorithm for SLN biopsy in the parotid gland. Int J Clin Oncol 15:504–507CrossRefPubMed

Hayashi T, Furukawa H, Oyama A et al (2012) Dominant lymph drainage in the facial region: evaluation of lymph nodes of facial melanoma patients. Int J Clin Oncol 17:330–335CrossRefPubMed

Hayashi T, Furukawa H, Oyama A et al (2012) Sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green in cutaneous head and neck/lip mucosa melanomas. Head Neck 34:758–761CrossRefPubMed

Kuwahara H, Furukawa H, Kitamura K et al (2011) Sentinel lymph node detection in melanoma using real-time fluorescence navigation with indocyanine green. Skin Cancer 26:55–58CrossRef

10.

Nguyen CL, McClay EF, Cole DJ et al (2001) Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 181:8–11CrossRefPubMed

11.

Paek SC, Griffith KA, Johnson TM et al (2007) The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109:100–108CrossRefPubMed

12.

Niakosari F, Kahn HJ, McCready D et al (2008) Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol 144:462–467CrossRefPubMed

13.

Egger ME, Gilbert JE, Burton AL et al (2011) Lymphovascular invasion as a prognostic factor in melanoma. Am Surg 77:992–997PubMed

14.

Stucky CC, Gray RJ, Dueck AC et al (2010) Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg 200:770–775CrossRefPubMed

15.

Hirono S, Tani M, Kawai M et al (2012) Identification of the lymphatic drainage pathways from the pancreatic head guided by indocyanine green fluorescence imaging during pancreaticoduodenectomy. Dig Surg 29:132–139CrossRefPubMed

16.

Inoue S, Shiina H, Mitsui Y et al (2013) Identification of lymphatic pathway involved in the spread of bladder cancer: evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green. Can Urol Assoc J 7:E322–328CrossRefPubMedPubMedCentral

17.

Suami H, Pan WR, Taylor GI (2007) Changes in the lymph structure of the upper limb after axillary dissection: radiographic and anatomical study in a human cadaver. Plast Reconstr Surg 120:982–991CrossRefPubMed

18.

Ballo MT, Bonnen MD, Garden AS et al (2003) Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97:1789–1796CrossRefPubMed

19.

Burmeister BH, Mark Smithers B, Burmeister E et al (2006) A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma−Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 81:136–142CrossRefPubMed

20.

Henderson MA, Burmeister BH, Ainslie J et al (2015) Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 16:1049–1060CrossRefPubMed

Title: Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma
Authors: Toshihiko Hayashi
Hiroshi Furukawa
Takashi Kitamura
Ryuji Shichinohe
Naoki Murao
Akihiko Oyama
Emi Funayama
Taku Maeda
Yuhei Yamamoto
Publication date: 01-06-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1085-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Effect of intraoperative radiotherapy in the treatment of retroperitoneal sarcoma

Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma

Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan

Multivariate evaluation of Thyroid Imaging Reporting and Data System (TI-RADS) in diagnosis malignant thyroid nodule: application to PCA and PLS-DA analysis

Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer

Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer